Seasonal variations of proximate composition and fatty acid profiles of wild brown trout (Salmo trutta macrostigma Dumeril, 1858) caught from the Munzur River, Tunceli-Turkey were investigated in ...this study. It was determined that wild brown trout was high in mono-unsaturated, poly-unsaturated and saturated fatty acids, respectively. Cl8:1 omega-9 (oleic acid) was the most abundant fatty acid in all seasons ranging from 20.27 to 29.35%. C22:6 omega-3 (docosahexaenoic acid-DHA), C18:3 omega-3c (cis-linolenic acid), C18:2 omega-6c (linoleic acid), and C20:5 omega-3 (eicosapentaenoic acid-EPA) were found to be predominant fatty acids in PUFAs. As a conclusion, wild brown trout living in Munzur river could be considered as an important protein and omega-3 fatty acid source according to the nutritional quality results evaluated in terms of proximate and fatty acid composition.Original Abstract: Bu calismada Munzur Nehri, Tunceli -Turkiye'den yakalanan dogal kahverengi alabaliklann (Salmo trutta macrostigma Dumeril, 1858) vucut kompozisyonu ve yag asidi profillerinin mevsimsel olarak degisimi arastirilmistir. Dogal kahverengi alabaliklann en coktan aza dogru sirasiyla mono-doymamis, coklu-doymamis ve doymus yag asitlerini icerdigi tespit edilmistir. Cl8:1 omega-9 (oleik asit) %20,27-29,35 arasinda degisen oranlarla birlikte butun mevsimlerde en baskin yag asidi olarak bulunmustur. C22:6 omega-3 (dokosahekzaenoik asit-DHA), 08:3 omega-3c (cis-linolenik asit), 08:2 omega-6c (linoleik asit) ve C20:5 omega-3 (eikosapentaenoik asit-EPA) coklu doymamis yag asitleri arasinda en baskin olanlandir. Sonuc olarak, vucut ve yag kompozisyonu acisindan degerlendirilmis besinsel kalite sonuclarina gore, Munzur nehri'nde yasayan dogal kahverengi alabaliklann onemli bir protein ve omega-3 yag asidi kaynagi oldugu dusunulebilir.
Tourniquet pain is one of the major obstacles for intravenous regional anesthesia. We aimed to compare tramadol and lornoxicam used in intravenous regional anesthesia as regards their effects on the ...quality of anesthesia, tourniquet pain and postoperative pain as well.
After the ethics committee approval 51 patients of ASA physical status I–II aged 18–65 years were enrolled. The patients were divided into three groups. Group P (n=17) received 3mg/kg 0.5% prilocaine; group PT (n=17) 3mg/kg 0.5% prilocaine+2mL (100mg) tramadol and group PL (n=17) 3mg/kg 0.5% prilocaine+2mL (8mg) lornoxicam for intravenous regional anesthesia. Sensory and motor block onset and recovery times were noted, as well as tourniquet pains and postoperative analgesic consumptions.
Sensory block onset times in the groups PT and PL were shorter, whereas the corresponding recovery times were longer than those in the group P. Motor block onset times in the groups PT and PL were shorter than that in the group P, whereas recovery time in the group PL was longer than those in the groups P and PT. Tourniquet pain onset time was shortest in the group P and longest in the group PL. There was no difference regarding tourniquet pain among the groups. Group PL displayed the lowest analgesic consumption postoperatively.
Adding tramadol and lornoxicam to prilocaine for intravenous regional anesthesia produces favorable effects on sensory and motor blockade. Postoperative analgesic consumption can be decreased by adding tramadol and lornoxicam to prilocaine in intravenous regional anesthesia.
A dor relacionada ao torniquete é um dos maiores obstáculos para a anestesia regional intravenosa (ARIV). Nosso objetivo foi comparar tramadol e lornoxicam usados em ARIV em relação aos seus efeitos sobre a qualidade da anestesia, dor relacionada ao torniquete e dor no pós-operatório.
Após a aprovação do Comitê de Ética, 51 pacientes com estado físico ASA I–II e idades entre 18–65 anos foram inscritos. Os pacientes foram divididos em três grupos. Grupo P (n=17) recebeu 3mg/kg de prilocaína a 0,5%; Grupo PT (n=17) 3mg/kg de prilocaína a 0,5%+2mL (100mg) de tramadol e Grupo PL (n=17) de 3mg/kg de prilocaína a 0,5%+2mL (8mg) de lornoxicam para ARIV. O início do bloqueio sensorial e motor e os tempos de recuperação foram registrados, bem como a dor relacionada ao torniquete e o consumo de analgésico no pós-operatório.
Os tempos de início do bloqueio sensorial foram mais curtos nos grupos PT e PL, enquanto que os tempos de recuperação correspondentes foram mais longos que os do Grupo P. Os tempos de início do bloqueio motor nos grupos PT e PL foram menores que no Grupo P, enquanto que o tempo de recuperação do grupo PL foi maior que os dos grupos P e PT. O tempo para início da dor relacionada ao torniquete foi menor no Grupo P e maior no Grupo PL. Não houve diferença em relação à dor relacionada ao torniquete entre os grupos. O Grupo PL apresentou o menor consumo de analgésicos no pós-operatório.
A adição de tramadol e lornoxicam à prilocaína para ARIV produz efeitos favoráveis sobre o bloqueio sensorial e motor. O consumo de analgésicos no pós-operatório pode ser reduzido com a adição de tramadol e lornoxicam à prilocaína em ARIV.
Aim: The coronary flow reserve (CFR) is a sign of endothelial dysfunction and early-stage coronary artery disease (CAD). Plasma atherogenic index (PAI) is related to subclinical CAD and may be used ...as a predictor of cardiovascular mortality. Our aim is to determine CFR and PAI in patients with AS and to investigate whether PAI can be used in the detection of early stage CAD.
Methods: The study population comprised 48 patients, who were diagnosed with AS based on modified New York criteria and 35 healthy volunteers. PAI values were calculated with the formula log 10 triglyceride (TG) / high-density lipoprotein (HDL).
Results: No difference was detected between the two groups for the demographic variables, including age, sex and BMI. The comparison of the groups for PAI and CFR demonstrated that PAI levels were observed to be significantly higher and CFR levels were observed to be significantly lower in the AS patients (p=0.01, p
Abstract Background: To date, several validated patient-based risk scores have been established to predict mortality and morbidity in patients presenting with ST-segment elevation myocardial ...infarction (STEMI). The Gensini score was originally developed to quantify the severity of coronary artery disease (CAD). Objectives: We intend to assess the association between severity of CAD assessed by Gensini score and in-hospital mortality in patients with STEMI undergoing primary percutaneous coronary intervention (P-PCI). Methods: A total of 539 patients presenting with acute STEMI, who underwent P-PCI within the first 12 hours from the onset of symptoms, were included. The severity of CAD was expressed as the sum of the Gensini scores for each lesion. Patients' demographic variables, medical histories and clinical features, as well as in hospital major adverse events were obtained from the medical reports. Results: Of these 539 patients, 416 (77.2%) were male and mean age was 59.14 ± 12.68 years. In-hospital mortality rate was 5.4% (29 patients; 16 men). Mortality rate was 10.5% in female patients and 3.8% in males (P = 0.004). Mean Gensini scores were significantly different in the comparison between patients who survived (54.54 ± 26.34) and those who died (80.17 ± 26.51) (P = 0.001). The multivariable Cox proportional hazards regression analysis model revealed that the Gensini score (P = 0.037), female gender (P = 0.039), serum urea levels (P = 0.041), uric acid levels (P = 0.008) and LVEF (P = 0.001) were independently associated with in-hospital mortality in patients with STEMI undergoing P-PCI. Conclusion: The Gensini score is independently associated with in-hospital mortality in STEMI patients treated with P-PCI. Therefore, it might play an important role in risk stratification of STEMI patients.
Despite a mostly self-limiting course, infantile hemangiomas can cause severe functional and/or cosmetic problems. The aim of this study was to determine the efficiency of propranolol treatment on ...infantile hemangiomas.
Sixty-seven infantile hemangioma patients were included in propranolol protocol in two institutions from 2009 to 2011. Participants included 36 boys and 31 girls. An associate protocol with radiology and pediatric cardiology was constructed for appropriate patient selection. Patients received a dose of 2 mg/kg/day, and all were admitted for the first 24 hours of therapy.
Sixty-seven patients were included in the study. Mean age at the initiation of therapy was 7 months (1 to 24 months), and eleven patients were older than 12 months of age when propranolol was started. All patients showed improvement with varying responses. No side effects were detected during the treatment.
Previously defined treatments for hemangiomas were efficient, yet had a limited usage because of side effects. Propranolol, with a high efficacy (not as total involution but stabilization and regression) and feasibility deserves to be the first line therapy for infantile hemangiomas even after the proliferation phase.
PDF
